Stocks Overview

LAST PRICE
13.5400
TODAY'S CHANGE (%)
Trending Up0.1400 (1.0448%)

Bid / Lots
13.4000/ 1
Ask / Lots
14.0000/ 4
Open / Previous Close
13.5500 / 13.4000
Day Range
Low 13.4700
High 13.7500
52 Week Range
Low 6.7000
High 18.0000
Volume
191,089
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Tuesday's close: 13.4
Time	Volume	ALVO
09:32 ET	1262	13.65
09:34 ET	1645	13.7
09:36 ET	12570	13.7
09:41 ET	1100	13.7
09:43 ET	600	13.69
09:45 ET	5319	13.65
09:48 ET	5244	13.65
09:50 ET	3400	13.66
09:52 ET	6910	13.69
09:54 ET	4000	13.65
09:56 ET	4156	13.69
09:57 ET	7897	13.65
09:59 ET	400	13.65
10:01 ET	32003	13.6
10:06 ET	700	13.53
10:08 ET	6937	13.62
10:10 ET	5100	13.6
10:14 ET	1200	13.61
10:15 ET	1213	13.62
10:17 ET	100	13.65
10:19 ET	100	13.65
10:24 ET	100	13.65
10:26 ET	100	13.65
10:30 ET	100	13.65
10:32 ET	100	13.65
10:33 ET	200	13.65
10:37 ET	100	13.65
10:39 ET	700	13.65
10:44 ET	300	13.595
10:50 ET	100	13.65
10:51 ET	100	13.65
10:53 ET	100	13.64
10:55 ET	1100	13.64
11:04 ET	100	13.65
11:08 ET	100	13.635
11:11 ET	100	13.65
11:15 ET	100	13.65
11:18 ET	100	13.65
11:22 ET	100	13.65
11:26 ET	100	13.65
11:29 ET	200	13.65
11:31 ET	1100	13.65
11:33 ET	2200	13.65
11:45 ET	100	13.65
11:49 ET	100	13.65
11:54 ET	100	13.64
11:58 ET	100	13.64
12:02 ET	100	13.64
12:05 ET	501	13.6251
12:14 ET	100	13.63
12:20 ET	100	13.64
12:23 ET	100	13.64
12:27 ET	100	13.64
12:32 ET	100	13.64
12:36 ET	500	13.63
12:45 ET	100	13.64
12:50 ET	200	13.635
12:57 ET	100	13.63
01:03 ET	300	13.63
01:06 ET	700	13.63
01:12 ET	200	13.625
01:17 ET	100	13.63
01:21 ET	100	13.63
01:30 ET	100	13.62
01:35 ET	300	13.62
01:48 ET	100	13.58
01:51 ET	100	13.61
01:55 ET	100	13.61
02:00 ET	100	13.61
02:04 ET	100	13.61
02:08 ET	100	13.61
02:11 ET	100	13.61
02:15 ET	100	13.61
02:20 ET	100	13.61
02:24 ET	100	13.61
03:00 ET	1100	13.61
03:02 ET	100	13.61
03:03 ET	100	13.5938
03:05 ET	100	13.61
03:07 ET	100	13.61
03:09 ET	100	13.61
03:14 ET	100	13.61
03:16 ET	200	13.61
03:18 ET	100	13.61
03:20 ET	100	13.61
03:23 ET	100	13.61
03:25 ET	100	13.61
03:27 ET	100	13.6
03:30 ET	100	13.61
03:32 ET	100	13.61
03:34 ET	100	13.61
03:36 ET	900	13.58
03:38 ET	100	13.58
03:39 ET	200	13.55
03:41 ET	300	13.555
03:43 ET	200	13.555
03:45 ET	4453	13.53
03:48 ET	200	13.56
03:50 ET	200	13.56
03:52 ET	400	13.55
03:54 ET	400	13.55
03:56 ET	23440	13.5
03:57 ET	1100	13.495
03:59 ET	17339	13.54

Data delayed at least 15 minutes.

Today
- Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi(R) (golimumab), from 17 hours ago by Dow Jones
  17 hours ago by Dow Jones
Apr 19, 2024
- Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira(R) (adalimumab), from 6:10AM ET on Friday Apr 19, 2024 by Dow Jones
  6:10AM ET on Friday Apr 19, 2024 by Dow Jones
Apr 16, 2024
- DJ Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment, from 6:04PM ET on Tuesday Apr 16, 2024 by Dow Jones
  6:04PM ET on Tuesday Apr 16, 2024 by Dow Jones
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI(TM) (ustekinumab-aekn), biosimilar to Stelara(R) (ustekinumab), from 5:43PM ET on Tuesday Apr 16, 2024 by Dow Jones
  5:43PM ET on Tuesday Apr 16, 2024 by Dow Jones
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI(TM) (ustekinumab-aekn), biosimilar to Stelara(R) (ustekinumab), from 5:30PM ET on Tuesday Apr 16, 2024 by Dow Jones
  5:30PM ET on Tuesday Apr 16, 2024 by Dow Jones

1 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesALVO Alvotech SA	3.6B	-5.6x	---
United StatesBHVN Biohaven Ltd	3.5B	-6.8x	---
United StatesCRNX Crinetics Pharmaceuticals Inc	3.4B	-11.7x	---
United StatesIBRX Immunitybio Inc	3.7B	-4.3x	---
United StatesACLX Arcellx Inc	2.9B	-35.5x	---
United StatesIOVA Iovance Biotherapeutics Inc	3.3B	-6.2x	---
As of 2024-04-24

Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Contact Information

Headquarters: 9, Rue De BitbourgLUXEMBOURG, Luxembourg 1273
Phone: ---
Fax: ---

Executives

Executive Chairman of the Board, Chief Executive Officer, Founder: Robert Wessman
Independent Deputy Chairman of the Board: Richard Davies
Chief Financial Officer: Joel Morales
Chief Operating Officer: Faysal Kalmoua
Chief Scientific Officer: Joseph Mcclellan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$3.6B
Revenue (TTM)	$93.4M
Shares Outstanding	266.8M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.03
EPS	$-2.40
Book Value	$-3.49
P/E Ratio	-5.6x
Price/Sales (TTM)	38.3
Price/Cash Flow (TTM)	---
Operating Margin	-403.05%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Alvotech SA
NASDAQ:ALVOUnited States

Search Criteria

Charts

Recent News

Today

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi(R) (golimumab), from 17 hours ago by Dow Jones

Apr 19, 2024

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira(R) (adalimumab), from 6:10AM ET on Friday Apr 19, 2024 by Dow Jones

Apr 16, 2024

DJ Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment, from 6:04PM ET on Tuesday Apr 16, 2024 by Dow Jones

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI(TM) (ustekinumab-aekn), biosimilar to Stelara(R) (ustekinumab), from 5:43PM ET on Tuesday Apr 16, 2024 by Dow Jones

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI(TM) (ustekinumab-aekn), biosimilar to Stelara(R) (ustekinumab), from 5:30PM ET on Tuesday Apr 16, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar